Home About Titan Pharmaceuticals Products Press Releases Financials Resources: Scientific Articles and Presentations Contact Us
About Titan Pharmaceuticals Inc.
«« back to press releases
TITAN PHARMACEUTICALS UPDATES TIMING OF CONFERENCE CALL ON THIRD QUARTER 2008 FINANCIAL RESULTS

Conference Call to be Held Tuesday, November 11, 2008

SOUTH SAN FRANCISCO, CA November 5, 2008 – Titan Pharmaceuticals, Inc. (AMEX: TTP) today announced that the Company will now release results for the quarter ended September 30, 2008 on Monday, November 10, 2008, after the market closes. Accordingly, the conference call to discuss the Company’s financial results, and progress towards 2008 goals will now take place at 10:00 a.m. (EST) on the following day, Tuesday, November 11, 2008, and will be hosted by Marc Rubin, M.D., President and Chief Executive Officer, Robert Farrell, Executive Vice President and Chief Financial Officer and Sunil Bhonsle, Executive Vice President and Chief Operating Officer.

The conference call can be accessed by visiting the investor relations section of the Company’s website at www.titanpharm.com. The call can also be accessed by dialing 1-866-356-4281 (domestic) or 1-617-597-5395 (international) five minutes prior to the start time and providing the passcode 11261265. A replay of the call will be available on the Titan website approximately two hours after completion of the call and will be archived for two weeks.

 

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (AMEX: TTP) is focused primarily on the late-stage development and commercialization of innovative treatments for central nervous system disorders. Probuphine, which utilizes Titan's proprietary ProNeura long term drug delivery technology, has demonstrated positive results in Phase III testing for treatment of opiate addiction, and the Company is planning to develop this validated sustained drug delivery technology for other potential treatment applications in which conventional treatment is limited by variability in blood drug levels and poor patient compliance. Products based on ProNeura technology can provide controlled drug release on an outpatient basis over extended periods of up to 6-12 months. Titan also has two other products, gallium maltolate and DITPA, in earlier stages of development. For more information, please visit the Company's website at www.titanpharm.com

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

 

Contact:

Company:
Robert Farrell
Executive Vice President & CFO

650-244-4990

Media/ Investors:

Jennifer Beugelmans
Pure Comminications
646-596-7473

Download PDF version